Journals / Hitit Medical Journal / 2026 / Cilt: 8 Sayı: 3

Paradoxical Increase in FIB-4 Despite Metabolic Improvement After Sleeve Gastrectomy: A Retrospective Study in Patients With MASLD

MASLD Hastalarında Sleeve Gastrektomi Sonrası Metabolik İyileşmeye Rağmen FIB-4'te Paradoksal Artış: Retrospektif Bir Çalışma

Pages
568–576
Publication Date
2026-10-14
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These findings suggest that early postoperative FIB-4 changes should be interpreted cautiously, as they may reflect transient alterations in platelet count and liver biochemistry during active weight loss rather than true fibrosis progression.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease, is strongly linked to obesity, insulin resistance, and type 2 diabetes.
📊
Key Findings & Data:This study aimed to evaluate short-term changes in the fibrosis-4 (FIB-4) index following laparoscopic sleeve gastrectomy and to assess concurrent changes in insulin resistance, liver enzymes, platelet count, and body mass index.
💡
Conclusion & Impact:These findings suggest that early postoperative FIB-4 changes should be interpreted cautiously, as they may reflect transient alterations in platelet count and liver biochemistry during active weight loss rather than true fibrosis progression.
🔬Design:Araştırma Makalesi
📍Scope:2023 Verileri
⚙️Variables:Sleeve gastrektomi · MASLD · FIB-4

Abstract

Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease, is strongly linked to obesity, insulin resistance, and type 2 diabetes. Bariatric surgery, particularly laparoscopic sleeve gastrectomy (LSG), is an established treatment for severe obesity and may improve hepatic steatosis and broader metabolic dysfunction. However, the interpretation of non-invasive fibrosis markers during rapid postoperative weight loss remains challenging, especially when biochemical improvement does not parallel fibrosis score trajectories. This study aimed to evaluate short-term changes in the fibrosis-4 (FIB-4) index following laparoscopic sleeve gastrectomy and to assess concurrent changes in insulin resistance, liver enzymes, platelet count, and body mass index. We also sought to determine whether early postoperative changes in FIB-4 should be interpreted cautiously during the active weight-loss period. Material and Method: This retrospective single-center study included 91 patients who underwent LSG between 2023 and 2025. Preoperative and postoperative data obtained during a follow-up period of 6–12 months included body weight, body mass index (BMI), liver enzymes, platelet count, fasting glucose, and fasting insulin. FIB-4 and HOMA-IR were calculated from routine laboratory measurements. Ultrasonographic steatosis was graded from 0 to 3. Pre- and postoperative comparisons were performed using non-parametric methods. Results: The cohort had a mean age of 39.19 ± 10.03 years and was predominantly female (80.2%). Significant postoperative reductions were observed in weight (118.92 ± 19.59 kg vs. 93.44 ± 17.70 kg, p<0.001), BMI (45.09 ± 6.26 kg/m² vs. 36.61 ± 4.92 kg/m², p<0.001), alanine aminotransferase, and HOMA-IR (6.92 ± 5.08 vs. 2.78 ± 1.48, p<0.001). In contrast, the mean FIB-4 score increased modestly but significantly from 0.57 ± 0.24 to 0.70 ± 0.51 (p=0.0016). Conclusion: LSG was associated with significant short-term metabolic improvement, including reductions in body weight, insulin resistance, and liver enzyme levels. Although the FIB-4 index increased modestly during the early postoperative period, both preoperative and postoperative values remained within the low-risk range. These findings suggest that early postoperative FIB-4 changes should be interpreted cautiously, as they may reflect transient alterations in platelet count and liver biochemistry during active weight loss rather than true fibrosis progression.

Özet

Amaç: Metabolik disfonksiyonla ilişkili steatotik karaciğer hastalığı (MASLD), obezite ve insülin direnci ile güçlü biçimde ilişkili olup, bariatrik cerrahi sonrasında karaciğer sonuçlarının değerlendirilmesi klinik açıdan önem taşımaktadır. Bu çalışmada laparoskopik sleeve gastrektomi (LSG) uygulanan hastalarda FIB-4 indeksindeki kısa dönem değişikliklerin yanı sıra insülin direnci, karaciğer enzimleri, trombosit sayısı ve vücut kitle indeksindeki değişimlerin değerlendirilmesi amaçlandı. Ayrıca aktif kilo kaybı döneminde FIB-4'te gözlenen erken postoperatif değişikliklerin dikkatli yorumlanması gerekip gerekmediği değerlendirildi. Gereç ve Yöntem: Bu retrospektif tek merkezli çalışmaya 2023–2025 yılları arasında LSG uygulanan 91 hasta dahil edildi. Ortalama 6–12 aylık izlem sürecinde preoperatif ve postoperatif vücut ağırlığı, vücut kitle indeksi (VKİ), karaciğer enzimleri, trombosit sayısı, açlık glukozu ve açlık insülini verileri kaydedildi. FIB-4 ve HOMA-IR rutin laboratuvar parametrelerinden hesaplandı. Ultrasonografik steatoz 0 ile 3 arasında derecelendirildi. Bulgular: Hastaların yaş ortalaması 39,19 ± 10,03 yıl olup olguların %80,2’si kadındı. Ameliyat sonrası kilo, VKİ, ALT ve HOMA-IR düzeylerinde anlamlı iyileşme saptandı. HOMA-IR değeri 6,92 ± 5,08’den 2,78 ± 1,48’e geriledi (p<0,001). Buna karşın FIB-4 skoru 0,57 ± 0,24’ten 0,70 ± 0,51’e hafif fakat anlamlı şekilde yükseldi (p=0,0016). Bu değişimler Sonuç: LSG, vücut ağırlığı, insülin direnci ve karaciğer enzimlerinde belirgin düzelme ile ilişkili bulunmuştur. Buna karşın, erken postoperatif dönemde FIB-4 skorunda mütevazı bir artış gözlenmiş, ancak hem preoperatif hem de postoperatif ortalama FIB-4 değerleri düşük risk aralığında kalmıştır. Bu bulgular, erken postoperatif dönemde FIB-4'te görülen değişikliklerin gerçek fibrozis progresyonundan ziyade, aktif kilo kaybı sürecindeki trombosit sayısı ve karaciğer biyokimyasındaki geçici değişiklikleri yansıtabileceğini düşündürmektedir. Bu nedenle bariatrik cerrahi sonrası FIB-4 sonuçları dikkatle yorumlanmalı ve mümkün olduğunda seri klinik değerlendirmeler ile elastografi gibi tamamlayıcı non-invaziv yöntemlerle desteklenmelidir.

🔖

Cite This Article

Değirmencioğlu, G., Çanakcı, M. H. (2026). Paradoxical Increase in FIB-4 Despite Metabolic Improvement After Sleeve Gastrectomy: A Retrospective Study in Patients With MASLD. Hitit Medical Journal, Cilt: 8 Sayı: 3, 568–576. https://doi.org/10.52827/hititmedj.1933446

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Obes Facts. 2024;17(4):374-444.
  2. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease. Hepatology. 2023;77(5):1797-1835.
  3. Younossi ZM, Zelber-Sagi S, Lazarus JV, et al. Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis. Gastroenterology. 2025;169(5):1017-1032.e2.
  4. Tilg H, Petta S, Stefan N, Targher G. Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults: A Review. JAMA. 2026;335(2):163-174
  5. Caussy C, Vergès B, Leleu D, et al. Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study. Diabetes Care. 2025;48(6):877-886.
  6. Liu H, Lefere S, Guillot A, et al. Bariatric Surgery for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Current Knowledge of Mechanisms. Hepatology. 2025;82(1):e0261.
  7. Lassailly G, Caiazzo R, Hollebecque A, et al. Bariatric Surgery Reduces Features of Non-Alcoholic Steatohepatitis in Morbidly Obese Patients. Gastroenterology. 2015;149(2):379-388.
  8. Seyedi A, Rabizadeh S, Karimpour Reyhan S, et al. Impact of Bariatric Surgery on Liver Fibrosis Indices Among Type 2 Diabetes Patients in a National Cohort. Sci Rep. 2025;15:1235.
  9. Yang CY, Chen JH, Chen CY, et al. Serial Changes in Metabolic Dysfunction-Associated Steatotic Liver Disease After Sleeve Gastrectomy and Their Associations With Abdominal Adiposity: A Prospective Cohort Study. Surg Obes Relat Dis. 2025;21(5):537-546.
  10. Alexander H, Falk R, Utz S, et al. Comparison of Different Liver Fibrosis Scores Following Sleeve Gastrectomy. Langenbecks Arch Surg. 2025;410:29.
  11. Kawai S, Kawai M, Hachiya H, et al. Analysis of Time-Dependent Changes in the FIB-4 Index After Bariatric Surgery. Sci Rep. 2022;12:15420.
  12. Albert SG, Elhajj II, Toro P, et al. FIB-4 as a Screening and Disease Monitoring Method in Pre-Bariatric Surgery Metabolic Dysfunction-Associated Steatotic Liver Disease. Obes Surg.2024;34(8):2698-2705
  13. Angulo P, Hui JM, Marchesini G, et al. The NAFLD Fibrosis Score: A Noninvasive System That Identifies Liver Fibrosis in Patients With NAFLD. Hepatology. 2007;45(4):846-854.
  14. Sterling RK, Lissen E, Clumeck N, et al. Development of a Simple Noninvasive Index to Predict Significant Fibrosis in Patients With HIV/HCV Coinfection. Hepatology. 2006;43(6):1317-1325.